RYR2 and catecholaminergic polymorphic ventricular tachycardia: When CPVT was first described by Leenhardt et al. [12] in 1995, it was considered a rare syndrome, but molecular screenings for RYR2 and CSQ2 mutations in children with positive exercise stress testing and absence of cardiac structural defects have improved diagnosis and prognosis of the disease.